Press releases

Orchard Therapeutics announces the opening of US operations in Foster City, California

Orchard is developing a global platform of ex-vivo autologous gene therapies in serious and life-threatening orphan diseases. In the United States, Orchard has collaborations with the University of California Los Angeles (“UCLA”) and Boston Children’s Hospital, and with leading manufacturing partners specialized in gene and cell therapy

Read more

Orchard Therapeutics announces presentations from UCL/GOSH and UCLA academic collaborators on clinical data in ADA-SCID

Orchard Therapeutics announces presentations from UCL/GOSH and UCLA academic collaborators on clinical data in ADA-SCID using ex-vivo lentiviral gene therapy at September 2016 ESID and ESGCT congresses

Read more

FierceBiotech names Orchard Therapeutics Limited as one of its “Fierce 15” Biotech Companies of 2016

Orchard Therapeutics Limited is proud to report that it has been named by FierceBiotech as one of 2016’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. The announcement was made during the FierceBiotech Drug Development Forum, which took place Monday September 19 in Boston, MA

Read more

Anne Dupraz-Poiseau, Ph.D. as Orchard's new Chief Regulatory Affairs Officer

Orchard Therapeutics Limited announces the appointment of Anne Dupraz-Poiseau, Ph.D. as Chief Regulatory Affairs Officer

Read more

Orchard hopes to bear the fruit of gene therapy

Daniel Levine from Global Gene RARE Cast spoke to Andrea Spezzi, Chief Medical Officer for Orchard about the company, its approach to gene therapy, and how its addressing the challenges of bringing such treatments to market

Read more